Loading the security overview…
Where the tokens are
| Quarter | EPS | EPS vs year ago | Revenue | Revenue vs year ago |
|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | $0.00 | — | $263.71M | +45.4% |
| Q1 FY26ended Mar 31, 2026 | $0.00 | — | $216.17M | — |
| Q4 FY25ended Dec 31, 2025 | $0.30 | — | $292.89M | — |
| Q3 FY25ended Sep 30, 2025 | $0.08 | — | $216.83M | — |
| Q2 FY25ended Jun 30, 2025 | −$7.97 | — | $181.40M | — |
| Q3 FY21ended Sep 30, 2021 | $2.79 | +272.0% | $100.83M | +36.5% |
| Q2 FY21ended Jun 30, 2021 | $2.04 | — | $85.70M | +23.4% |
| Q1 FY21ended Mar 31, 2021 | $1.91 | — | $80.80M | +16.9% |
| Q4 FY20ended Dec 31, 2020 | $0.67 | — | $81.57M | — |
| Q3 FY20ended Sep 30, 2020 | $0.75 | — | $73.89M | — |
| Q2 FY20ended Jun 30, 2020 | −$0.16 | — | $69.44M | — |
| Q1 FY20ended Mar 31, 2020 | −$0.20 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss.
Figures describe Caris Life Sciences shares, not any token. From Massive's standardised financials and the earnings calendar.
| — |
| $69.11M |
| — |